Headquartered in Maryland, USA, outside of Washington, D.C., 20/20 GeneSystems Inc. is a digital diagnostics company that utilizes machine learning and real-world data sets to improve the accuracy and usefulness of protein and antibody-based blood biomarker tests. Over the years, 20/20 has been awarded over $7 million NIH grants, and Ping An, one of the largest health insurance and digital health companies in China, is a large investor and board member. One of our flagship products is OneTest™: AI Powered Multi-Cancer Blood Test & Machine Learning Algorithm for Broad Spectrum Early Cancer Detection.

The foundation of OneTest™ is based on this East Asian testing paradigm, but our proprietary algorithms which is co-developed with the Chang Gung Memorial Hospital, Linkou, substantially improve the accuracy of standard biomarker testing by reducing the number of missed cancers by more than half.

OneTest™ is:
• The first A.I. powered (machine learning algorithms) multi-tumor marker early screening platform, through 10 plus years large clinical studies using real-world data involving over hundreds of thousands asymptomatic individuals from Taiwan and Chongqing
• A cloud accessible platform to improve the accuracy of tumor marker blood tests
• Useful in early detection of multiple types of cancer (lung, liver, colon, kidney, cervical, breast, etc.)
• Incorporates clinical factors (age, gender, smoking history, etc.)
• Stores & displays biomarker trends from repeat tests and calculates whether a rise in individual biomarker levels is significant
• Suggests repeat testing for those with increased likelihood of cancer
• Uses machine learning / AI
• Improve early cancers detections 2x-6x

East Asia is our most important market, everyday tens of millions of individuals in East Asia visit “Health Check Centers” where they are tested with many of the same biomarkers that are part of OneTest. Since 2019 we began to actively market OneTest™ in East Asia. In January 2020 we were one of only 11 companies (from over 500 applicants worldwide) selected to be part of the Ping An Cloud Accelerator in Shenzhen China. This gives us special access to various divisions and subsidiaries of this conglomerate. 2020 is setting up East Asia operation headquartered in Shenzhen, and has entered pilot program with Ping An medical division to develop China market.

We welcome the following alliances and collaborations with East Asia companies and organizations:
• Collaboration with Health Check Centers and Testing Labs – Improve the value of their services and distinguish over competition
• Collaboration with Health Insurance Companies – Promote early detection among insured population to lower costs of treating late stage cancers
• Collaboration with Telemedicine Companies – Improve the value of their services and promote early detection of cancers among their users, and distinguish over competition
• Collaboration with Tech Companies to construct Consumer Portal – Individuals upload their own biomarker levels and track their trends over time help to avoid deadly, advanced cancers

20/20 is raising capital on Website :
• $2,000,000 raised as of August 7, 2020
• SEC Qualified under Reg. A+ to go public
• Full transparency: Disclosures reviewed by SEC, FINRA, and licensed Broker / Dealers
• Public company audits
• Thousands of retail investors become consumers & brand advocates

CONTACT:
Jiming Zhou, PhD
20/20 GeneSystems, Inc.
9430 Key West Avenue, Suite 100, Rockville, Maryland 20850 U.S.A.
Email: jzhou@2020gene.com
Phone: +1 (703) 867-5722 （US）; Phone: +86 19923397469 (中国）
WeChat: jz20140509；WhatsApp: +1 (703) 867-5722;
Website